Research Reports | Market Assessment
November 2015

Acute Myeloid Leukemia | Niche and Rare Pharmacor | G7 | 2015

Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population.

A range of therapies are used to treat AML; however, the market is dominated by the use of agents that induce DNA damage. As drug treatments and clinical trial designs continue to evolve, novel agents with new mechanisms of action are set to enter this market.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports